New radiation approach aims to boost lung cancer treatment in poor responders
NCT ID NCT07670715
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots inside the tumor while sparing nearby healthy organs. The study will enroll 30 participants to see if this combination can improve tumor response and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lattice radiation therapy (a type of radiotherapy that delivers high and low radiation doses within the tumor) combined with chemoimmunotherapy
What this could lead to
If successful, this approach could offer a new treatment option for patients with advanced lung cancer who did not respond well to initial therapy, potentially improving tumor shrinkage and survival.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The combination therapy may cause side effects like radiation injury to the lungs, heart, or esophagus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••